Small Molecules

18 Jul 2017 Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
18 Jul 2017 CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis
18 Jul 2017 Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
18 Jul 2017 EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC)
18 Jul 2017 Samumed Successfully Completed Phase I Study for Potential Treatment of Idiopathic Pulmonary Fibrosis
18 Jul 2017 U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
17 Jul 2017 Proclara Biosciences Announces Pipeline Progress
14 Jul 2017 CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
14 Jul 2017 Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
14 Jul 2017 European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
14 Jul 2017 New Experimental Data on Anti-inflammatory Effects of ABX464, ABIVAX’s First-in-Class Drug Candidate to Achieve Functional Cure in HIV-Patients, Published in Nature Scientific Reports
12 Jul 2017 Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
12 Jul 2017 Neuraltus Announces Completion of Enrollment in Confirmatory Phase 2 Study of NP001 in ALS Patients with Systemic Inflammation
12 Jul 2017 Ocular Therapeutix™ Receives Complete Response Letter from FDA for DEXTENZA™ NDA
12 Jul 2017 U.S. FDA Confirms Amicus Therapeutics May Submit New Drug Application for Migalastat for Fabry Disease
11 Jul 2017 Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
11 Jul 2017 Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
11 Jul 2017 ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
11 Jul 2017 FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543
11 Jul 2017 Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium
11 Jul 2017 Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension
10 Jul 2017 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Children with Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
10 Jul 2017 Parkinson’s disease: Prexton announces initiation of phase II clinical testing
10 Jul 2017 Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I
08 Jul 2017 Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing